Agronomics (LSE:ANIC), the listed investor in cellular agriculture and alternative proteins, told the market on 13 November 2026 that portfolio company Solar Foods had received a positive scientific opinion from the European Food Safety Authority (EFSA) for its protein ingredient Solein. The announcement followed a portfolio update on 11 November. It is a regulatory step forward in Europe for one of the better-known holdings of this FTSE AIM All Share index constituent.

What the company does

Agronomics is an AIM-quoted Investment company that takes minority stakes in early-stage businesses. These companies use biotechnology, such as cell culture and precision fermentation, to produce meat, dairy, proteins and other materials without conventional livestock farming. Shareholders get listed exposure to a portfolio made up largely of private companies. The portfolio's value is reported through quarterly Net Asset Value (NAV) statements.

Latest developments

Solar Foods is a Finnish company that makes Solein, a protein produced by fermenting microbes using air and electricity. According to the 13 November announcement, the EFSA opinion moves Solein's EU novel food application into its final authorisation stage. That stage is estimated to take another seven to nine months, and European Commission approval would allow sales across the EU. The company adds that the opinion is expected to help offtake talks and the financing needed for a final investment decision on Solar Foods' second factory.

The company also says Agronomics has invested £5.2 million in Solar Foods, now carried at about £6.4 million. That is roughly 4.6% of its NAV of £139.5 million at 30 September 2026.

Other portfolio companies also reached milestones during 2026. On 1 April, All G secured a US FDA "no questions" letter. Tropic announced a product approval on 14 April and agreed to acquire Rahan Meristem on 25 June. On 7 May, Meatly completed a £10.4 million Series A round, and on 12 May Agronomics led a US$5 million investment in SuperMeat. Further updates covered HydGene and Bond Pet Foods on 4 June and Liberation Bioindustries on 29 September.

Financial picture

Agronomics publishes its NAV every quarter. The statement for 30 September 2026 was released on 20 October, after those for 30 June (10 July) and 31 March (18 May). The £139.5 million NAV figure above is taken from the Solar Foods release. A director/PDMR shareholding notice was filed on 14 July. As with other investment companies, Agronomics' shares can trade at a premium or a discount to NAV.

Sector and index context

Funding for alternative proteins boomed early in the decade and then fell back sharply, which pushed valuations down across the sector. Regulatory approvals, product launches and fresh funding rounds are therefore watched closely as signs that the industry is maturing. Within the FTSE AIM All Share Index, Agronomics (LSE:ANIC) is one of very few ways to gain diversified, listed exposure to the theme.

Key risks

Most portfolio companies are early-stage and loss-making and will need more capital. Valuing private companies involves judgement, and valuations can be cut. EFSA's opinion does not guarantee final EU authorisation, and regulatory timelines in other markets are also uncertain. Agronomics' ability to support its investees depends on its own resources. Consumer Demand for novel foods at scale has yet to be proven.

What to watch next

Investors will watch the European Commission authorisation process for Solein and Solar Foods' progress towards an investment decision on its second factory. The next quarterly NAV, for 31 December 2026, is also due. Further funding rounds across the portfolio and any realisations that turn paper gains into cash will be closely followed.